ALT

Altimmune, Inc. (ALT) | Rumor.io

Altimmune

ALT

Attention (50-day avg)0.04%

Attention rank (50-day avg)#205

Bullish sentiment (50-day avg)79%

Price to earnings ratio-2.95

Market capitalization575.8M

Earnings per share-0.76

Dividend yield (TTM)—

Revenue (annual)41K

Net income (annual)-88.1M

Social

What share of all stock conversation is about ALT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.04% -0.01	0.03% +0.01	0.03% 0	0.06% -0.06

Sep 29

Altimmune, Inc. has been hiring experienced professionals from the biopharmaceutical industry, including a Vice President, Global Controller and Principal Accounting Officer with 28 years of experience.
The company has been making progress in its AUD program, with a positive topline from a Phase 2 study and plans to request an FDA meeting for Phase 3.
Altimmune's potential partnership with a big pharma could provide non-dilutive funding and strategic validation, and the company is expected to make an announcement about business development at an upcoming conference.

Generated by AI

Sentiment

Of the messages about ALT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	60.16% +2.88	63.97% -16.49	80.8% +2.73	78.15% +1.4
Bearish	39.84% -2.88	36.03% +16.49	19.2% -2.73	21.85% -1.4

Bullish· Sep 24

$ALT's long-term IP strategy for AUD and ALD is now fully visible to acquirers, de-risking the asset and driving up its premium valuation.
Evercore lowered its PT from $18 to $17 due to a more conservative treatment-rate assumption for AUD, but kept an Outperform rating.
The company's future looks bright, with the obesity market now being moved into by Novo, and AUD FDA meeting outcome expected to be positive, with the stock price likely to recover after the meeting.

Bearish· Sep 24

Altimmune, Inc. (ALT) has been down 15% since the Fireside chat, indicating a decline in investor confidence.
The stock has been experiencing a significant decline, with one user commenting that it's "like watching Mr. Orange in Reservoir Dogs, just bleeding out all over that warehouse floor."
The company's recent fundraising efforts may have led to dilution, with one user comparing the current situation to the dilution that occurred after a previous price pump, stating that it's "still not able to recover."

Generated by AI

Topics

Of the messages about ALT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	82.35%	40.12%	45.2%	33.14%
Technical Analysis	17.65%	47.9%	45.76%	45.7%
Analysts	0%	7.19%	6.73%	10.84%
Controversies	0%	4.79%	1.32%	2.28%
Macro	0%	0%	0.99%	6.65%
Earnings	0%	0%	0%	1.39%

Analysts· Jul 10

Goldman Sachs downgraded Altimmune (ALT) to Sell with a $1 price target, citing lack of differentiation in the MASH/obesity space and funding concerns.
Citizens JMP maintained a Market Outperform rating with a $15 price target, highlighting Altimmune's strong cash position, best-in-class MASH resolution, and potential for a Phase 3 trial.
Analysts' opinions on Altimmune's stock price vary widely, with a mean price target of $18.89 and a median of $20, while Goldman Sachs' downgrade to Sell with a $1 price target is seen as overly bearish by some.

Announcements· Mar 11

Altimmune, Inc. (ALT) is expected to benefit from the patent cliff in the pharmaceutical industry, making it a potential acquisition target.
A forthcoming discussion with Barclay's analyst is expected to delve into key topics such as Altimmune's Phase 3 timeline, global expansion plans, funding, partnership interest, and target markets.
Altimmune's drug, Pemvi, has the potential to be combined with other products, such as statins for cardiovascular and weight loss, or FGF21/THb for metabolic disorders, making it an attractive plug-in product for potential partners.

Macro· Apr 3

The US has imposed 20% tariffs on the EU, with the EU's average tariff at 5.3% compared to the US's 4.4%, and the US administration has been accused of misusing VAT logic and exchange rates to justify the tariffs.
The tariffs are expected to have a significant impact on the US economy, leading to higher inflation, reduced consumption, and potentially even stagflation, which could result in higher interest rates, slow growth, and widespread unemployment.
The pharmaceutical sector, including Altimmune, is largely unaffected by the tariffs, and the overall market is expected to benefit from the situation, with small caps and bios potentially seeing increased activity and prices.

Technical Analysis· Feb 24

$ALT is experiencing strength, potentially due to positioning ahead of the next catalyst window, with traders re-pricing the setup after the recent $75M financing.
Technical indicators, including the 50 and 200 DMA, are currently in favor of $ALT, with the stock trading above these levels and showing signs of accumulation.
The weekly chart for $ALT is showing positive signs, including a positive MACD, a fast stochastic cross, and the 20 EMA crossing the 50 SMA, suggesting a potential move to the upside.

Generated by AI

Community

Of the messages about ALT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	98.05%	97.25%	92.91%	86.87%
Newcomers	1.95%	2.75%	7.09%	13.13%

Regulars· Sep 29

The regulars are focused on the interesting backdrop around pemvi, with several big pharma companies exploring new therapeutic areas or making large deals, including Lilly, Sanofi, Novo, and Gilead.
Altimmune's recent hiring of a Principal Accounting Officer suggests that a milestone or royalty-based partnership is in the works for Phase 3 AUD, with the possibility of non-dilutive funding.
The company's recent 8-K filing and new HQ location announcement are seen as potentially significant news events, and the regulars are speculating about the reasons behind the delay in filing the 8-K.

Newcomers· Aug 12

Many newcomers are focused on the company's pipeline and its potential for growth, with some expressing excitement about the pipeline's robustness and the company's ability to trade at cash value.
Some newcomers are concerned about the company's potential for dilution, with a few expressing skepticism about the company's ability to fund its operations without issuing more shares and warrants.
A few newcomers are comparing the company to another asset, NAMI, which they believe has potential for a massive china squeeze rally, and are taking positions in NAMI based on this comparison.

Generated by AI

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinic

7d agoYahoo Finance

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

18d agoYahoo Finance

Altimmune at Wells Fargo healthcare conference: pemvidutide push

19d agoInvesting.com

Altimmune’s (ALT) Three Liver Trials Move Forward At Once

22d agoYahoo Finance

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clin

27d agoYahoo Finance Singapore

Also Discussed

Investors talking about ALT also mention

#	Name	Attention
1	TERN - Terns Pharmaceuticals, Inc.	——
2	Viking Therapeutics, Inc.VKTX	0.18%0
3	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
4	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
5	MTSR - Metsera, Inc.	——
6	ETNB - 89bio, Inc.	——
7	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
8	Inventiva S.A. American Depositary ReceiptIVA	0%-0.01
9	Seres Therapeutics Inc.MCRB	0%0
10	Sagimet Biosciences Inc. Series A Common StockSGMT	0%0

Altimmune, Inc.

Healthcare
Biotechnology

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases. The company’s lead product candidate, pemvidutide, is a dual GLP-1 and glucagon receptor agonist being studied for conditions such as metabolic dysfunction-associated steatohepatitis, alcohol use disorder, alcohol-associated liver disease, and obesity. Altimmune is also developing HepTcell, an immunotherapeutic program designed for chronic hepatitis B. Through these programs, Altimmune operates at the intersection of metabolic medicine, hepatology, and immunotherapy, with a pipeline aimed at addressing complex diseases that currently have limited treatment options. The company is headquartered in Gaithersburg, Maryland.

Website

Location

910 Clopper Road

Gaithersburg, MD, 20878

United States

Social

What share of all stock conversation is about ALT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.04% -0.01	0.03% +0.01	0.03% 0	0.06% -0.06

Sep 29

Altimmune, Inc. has been hiring experienced professionals from the biopharmaceutical industry, including a Vice President, Global Controller and Principal Accounting Officer with 28 years of experience.
The company has been making progress in its AUD program, with a positive topline from a Phase 2 study and plans to request an FDA meeting for Phase 3.
Altimmune's potential partnership with a big pharma could provide non-dilutive funding and strategic validation, and the company is expected to make an announcement about business development at an upcoming conference.

Generated by AI

Sentiment

Of the messages about ALT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	60.16% +2.88	63.97% -16.49	80.8% +2.73	78.15% +1.4
Bearish	39.84% -2.88	36.03% +16.49	19.2% -2.73	21.85% -1.4

Bullish· Sep 24

$ALT's long-term IP strategy for AUD and ALD is now fully visible to acquirers, de-risking the asset and driving up its premium valuation.
Evercore lowered its PT from $18 to $17 due to a more conservative treatment-rate assumption for AUD, but kept an Outperform rating.
The company's future looks bright, with the obesity market now being moved into by Novo, and AUD FDA meeting outcome expected to be positive, with the stock price likely to recover after the meeting.

Bearish· Sep 24

Altimmune, Inc. (ALT) has been down 15% since the Fireside chat, indicating a decline in investor confidence.
The stock has been experiencing a significant decline, with one user commenting that it's "like watching Mr. Orange in Reservoir Dogs, just bleeding out all over that warehouse floor."
The company's recent fundraising efforts may have led to dilution, with one user comparing the current situation to the dilution that occurred after a previous price pump, stating that it's "still not able to recover."

Generated by AI

Topics

Of the messages about ALT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	82.35%	40.12%	45.2%	33.14%
Technical Analysis	17.65%	47.9%	45.76%	45.7%
Analysts	0%	7.19%	6.73%	10.84%
Controversies	0%	4.79%	1.32%	2.28%
Macro	0%	0%	0.99%	6.65%
Earnings	0%	0%	0%	1.39%

Analysts· Jul 10

Goldman Sachs downgraded Altimmune (ALT) to Sell with a $1 price target, citing lack of differentiation in the MASH/obesity space and funding concerns.
Citizens JMP maintained a Market Outperform rating with a $15 price target, highlighting Altimmune's strong cash position, best-in-class MASH resolution, and potential for a Phase 3 trial.
Analysts' opinions on Altimmune's stock price vary widely, with a mean price target of $18.89 and a median of $20, while Goldman Sachs' downgrade to Sell with a $1 price target is seen as overly bearish by some.

Announcements· Mar 11

Altimmune, Inc. (ALT) is expected to benefit from the patent cliff in the pharmaceutical industry, making it a potential acquisition target.
A forthcoming discussion with Barclay's analyst is expected to delve into key topics such as Altimmune's Phase 3 timeline, global expansion plans, funding, partnership interest, and target markets.
Altimmune's drug, Pemvi, has the potential to be combined with other products, such as statins for cardiovascular and weight loss, or FGF21/THb for metabolic disorders, making it an attractive plug-in product for potential partners.

Macro· Apr 3

The US has imposed 20% tariffs on the EU, with the EU's average tariff at 5.3% compared to the US's 4.4%, and the US administration has been accused of misusing VAT logic and exchange rates to justify the tariffs.
The tariffs are expected to have a significant impact on the US economy, leading to higher inflation, reduced consumption, and potentially even stagflation, which could result in higher interest rates, slow growth, and widespread unemployment.
The pharmaceutical sector, including Altimmune, is largely unaffected by the tariffs, and the overall market is expected to benefit from the situation, with small caps and bios potentially seeing increased activity and prices.

Technical Analysis· Feb 24

$ALT is experiencing strength, potentially due to positioning ahead of the next catalyst window, with traders re-pricing the setup after the recent $75M financing.
Technical indicators, including the 50 and 200 DMA, are currently in favor of $ALT, with the stock trading above these levels and showing signs of accumulation.
The weekly chart for $ALT is showing positive signs, including a positive MACD, a fast stochastic cross, and the 20 EMA crossing the 50 SMA, suggesting a potential move to the upside.

Generated by AI

Community

Of the messages about ALT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	98.05%	97.25%	92.91%	86.87%
Newcomers	1.95%	2.75%	7.09%	13.13%

Regulars· Sep 29

The regulars are focused on the interesting backdrop around pemvi, with several big pharma companies exploring new therapeutic areas or making large deals, including Lilly, Sanofi, Novo, and Gilead.
Altimmune's recent hiring of a Principal Accounting Officer suggests that a milestone or royalty-based partnership is in the works for Phase 3 AUD, with the possibility of non-dilutive funding.
The company's recent 8-K filing and new HQ location announcement are seen as potentially significant news events, and the regulars are speculating about the reasons behind the delay in filing the 8-K.

Newcomers· Aug 12

Many newcomers are focused on the company's pipeline and its potential for growth, with some expressing excitement about the pipeline's robustness and the company's ability to trade at cash value.
Some newcomers are concerned about the company's potential for dilution, with a few expressing skepticism about the company's ability to fund its operations without issuing more shares and warrants.
A few newcomers are comparing the company to another asset, NAMI, which they believe has potential for a massive china squeeze rally, and are taking positions in NAMI based on this comparison.

Generated by AI

Altimmune

Social

Sep 29

Bullish· Sep 24

Bearish· Sep 24

Analysts· Jul 10

Announcements· Mar 11

Macro· Apr 3

Technical Analysis· Feb 24

Regulars· Sep 29

Newcomers· Aug 12

Altimmune appoints Richard Menziuso as vice president and principal accounting officer

Altimmune to Participate in Stifel Cardiometabolic Forum

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune at Wells Fargo healthcare conference: pemvidutide push

Altimmune’s (ALT) Three Liver Trials Move Forward At Once

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Also Discussed

Altimmune, Inc.

Company Information

Location

Altimmune appoints Richard Menziuso as vice president and principal accounting officer

Altimmune to Participate in Stifel Cardiometabolic Forum

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune at Wells Fargo healthcare conference: pemvidutide push

Altimmune’s (ALT) Three Liver Trials Move Forward At Once

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Also Discussed

Social

Sep 29

Bullish· Sep 24

Bearish· Sep 24

Analysts· Jul 10

Announcements· Mar 11

Macro· Apr 3

Technical Analysis· Feb 24

Regulars· Sep 29

Newcomers· Aug 12